Press Releases InMed to Present at the Emerging Growth Conference June 10, 2024 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update May 14, 2024 Read More » InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board April 18, 2024 Read More » InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration April 16, 2024 Read More » InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies April 4, 2024 Read More » InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance March 20, 2024 Read More » InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update February 13, 2024 Read More » InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer February 9, 2024 Read More » InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET January 18, 2024 Read More » InMed Pharmaceuticals Provides Business Update and Milestones for 2024 January 16, 2024 Read More » InMed Announces Results of 2023 Annual General Meeting December 19, 2023 Read More » InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration November 29, 2023 Read More » InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update November 14, 2023 Read More » InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 November 2, 2023 Read More » InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules October 26, 2023 Read More » InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules October 24, 2023 Read More » InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies October 24, 2023 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update September 29, 2023 Read More » InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance September 22, 2023 Read More » InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update May 14, 2024 Read More »
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board April 18, 2024 Read More »
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration April 16, 2024 Read More »
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies April 4, 2024 Read More »
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update February 13, 2024 Read More »
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer February 9, 2024 Read More »
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET January 18, 2024 Read More »
InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration November 29, 2023 Read More »
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update November 14, 2023 Read More »
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 November 2, 2023 Read More »
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules October 26, 2023 Read More »
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules October 24, 2023 Read More »
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies October 24, 2023 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update September 29, 2023 Read More »
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance September 22, 2023 Read More »
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023 Read More »
